XmAb24306
- Generic Name
- XmAb24306
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
XmAb24306 is an investigational cancer immunotherapy. It is a heterodimeric interleukin (IL)-15/IL-15-receptor alpha (IL-15Ra) complex fused to a bispecific Fc domain.
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma
Phase 1
Recruiting
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2022-12-12
- Last Posted Date
- 2024-12-31
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT05646836
- Locations
- 🇬🇷
University of Athens, Hematological Clinic,, Athens, Greece
🇦🇺Royal Adelaide Hospital, Adelaide, South Australia, Australia
🇦🇺Peter Maccallum Cancer Centre, Melbourne, Victoria, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath